TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Gt Biopharma
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GT Biopharma reported progress on its Phase 1 clinical trial for GTB-3650, a TriKE® therapy targeting CD33-expressing hematologic malignancies, with successful advancement to Cohort 4 and no observed safety issues. The company plans to provide a trial update in Q1 2026 and anticipates submitting an IND for GTB-5550 in late December 2025.

Insights
GTBP   positive

Positive trial progression, no safety concerns, continued research advancement, and planned IND submission indicate promising development of therapeutic platform